Proteostasis Teams Up With Elan In $50M Neurodegenerative Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Irish company will get a 24% stake in the U.S. biotech as part of an R&D collaboration centered around neurodegenerative diseases.
You may also be interested in...
New Cambridge-Elan Centre To Focus On Alzheimer's With $10 Million From Elan
Ireland's Elan Corp. launches a $10 million center for neuroscience R&D with University of Cambridge academics.
Cleave Biosciences Takes $42M Series A Round
Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.
Cleave Biosciences Takes $42M Series A Round
Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.